Monoclonal antibodies targeting receptors of immune inhibitory pathways, including cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), programmed death protein 1 (PD-1), and its ligand 1 (PD-L1), work by restoring the response of T lymphocytes and NK cells against tumor cells and reducing their escape from immune surveillance [4]. The gene discussed is CTLA4; the disease is neoplasm.